期刊
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020
卷 71, 期 -, 页码 1-15出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-053117-123246
关键词
metabolic surgery; bariatric surgery; type 2 diabetes; cardiovascular risk factor; weight loss; diabetes remission
Metabolic surgery is increasingly becoming recognized as a more effective treatment for patients with type 2 diabetes (T2D) and obesity as compared to lifestyle modification and medical management alone. Both observational studies and clinical trials have shown metabolic surgery to result in sustained weight loss (20-30%), T2D remission rates ranging from 23% to 60%, and improvement in cardiovascular risk factors such as hypertension and dyslipidemia. Metabolic surgery is cost-effective and relatively safe, with perioperative risks and mortality comparable to low-risk procedures such as cholecystectomy, hysterectomy, and appendectomy. International diabetes and medical organizations have endorsed metabolic surgery as a standard treatment for T2D with obesity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据